Medvance Clinical Research Selects Trialstat's ClinicalAnalytics 4.0 for U.K.-Based Medical Device Study
U.K.-based CRO selects TrialStat for its on demand EDC platform and comprehensive service offering.
Ottawa, ON (PRWEB) September 17, 2007 -- TrialStat Corporation, a clinical data solutions on demand company, today continued its international growth with Medvance Clinical Research’s (Medvance) selection of ClinicalAnalytics 4.0 (CA) as its electronic data capture (EDC) platform for a medical device study. Based in the United Kingdom, Medvance, a contract research organization (CRO), chose CA for its user configurability, ease of use, responsive customer service and attractive subscription pricing model. For nearly 10-years, Medvance has been providing services and solutions to the medical device, pharmaceutical and healthcare industries in the United Kingdom.
CA’s 100% browser configurable platform allows research professionals to deploy study specific EDC nearly twice as fast as the industry average. TrialStat’s on demand EDC platform also integrates web and flexible data capture technologies, including image-based forms, standalone and handheld devices. CA is fully compliant with international regulatory standards, including the FDA's 21 CFR Part 11 and the good electronic clinical trial practices required by the European Medicines Agency (EMEA) and Health Canada.
“As a fast growing CRO, we wanted an EDC partner that could deliver data management, study design and data archiving all under one roof,” said Janette Benaddi, Chief Executive Officer, Medvance. “These value-added services along with the flexibility of CA allowed us to deploy our study quickly, which has enhanced our ability to deliver results efficiently and cost-effectively for our client.”
“Medical device companies and their CROs require a nimble on demand EDC solution that can be up and running quickly to address this sector’s specific needs,” said Jonathan Barker, President and CEO, TrialStat. “CA provides an optimal combination of speed and ease-of-use that lets customers manage their trials cost-effectively, eliminating those capital expenditures typically associated with client server and ASP software environments. In addition, our partnership with Medvance has further expanded the number of clinical studies hosted by TrialStat outside of the Americas. TrialStat’s significant experience in working with different regulatory jurisdictions and in multiple languages continues to be a critical factor in our ability to deliver excellent products and services to our global customer base.”
ABOUT TRIALSTAT
TrialStat Corporation provides innovative clinical data solutions on demand that optimize the collection and management of research to enable customers to accelerate the commercialization of new life science products. CA 4.0 is a robust and scaleable Web-based EDC on demand platform used by leading biopharma organizations. SRS 4.0™ automates systematic reviews using real-time collaboration and management tools, while ESRNexus™ (www.esrnexus.com) is the most comprehensive and free Web-based search engine for evidence-based reference literature. More information about TrialStat is available at www.trialstat.com.
ABOUT MEDVANCE
Medvance was founded in 1997 by Janette Benaddi, a qualified nurse and teacher, who has over 18 years experience in the industry. Medvance has built up a very dedicated team of professionals coming from both device and pharmaceutical backgrounds. They have a network of monitors throughout Europe. Members of this network are extremely experienced and possess the local knowledge needed to ensure that studies are professionally conducted.
ClinicalAnalytics 4.0, SRS 4.0 and ESRNexus are registered trademarks of TrialStat Corporation.
For media inquiries, please contact:
Chris Wright
TrialStat Corporation
613-741-9909 ext 155
# # #
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/SG9yci1FbXB0LVBpZ2ctTWFnbi1UaGlyLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.